GB Sciences earns licensing revenue but faces cash crunch, heavy debt and going‑concern risk

Snapshot - GB Sciences, Inc. (OTCMKTS: GBLX)

What's happening inside: GB Sciences is a small, IP-heavy biopharma focused on plant‑inspired drug candidates (Parkinson's, chronic pain, MCAS, cardiovascular, CRS). Management is advancing preclinical programs, monetizing IP through a licensing deal with EndoPure (royalties + upfront payments), and raising short‑term cash via convertible notes and warrant exercises. The business remains cash‑constrained with substantial debt and a formal going‑concern disclosure.

Quick take - positives vs. negatives (income statement & operations)

- Positive: Recognized first material revenue from licensing/royalties - Revenue (three months ended Dec 31, 2024): $97,235; Gross profit: $97,235.
- Positive: General & administrative expenses decreased (3-months): $163,826 vs $234,007 (prior year quarter).
- Positive: Active IP portfolio and recent licensing (EndoPure) with commercial terms (royalty 5% of gross sales; upfront ~$125,000 to Catalent; annual prepaid minimum royalty $50,000 per product for 3 years).
- Negative: Net loss remains - Net loss (three months ended Dec 31, 2024): $(100,355); Net loss (nine months ended Dec 31, 2024): $(575,899).
- Negative: No operating cash cushion - Cash at Dec 31, 2024: $3,016; Net cash used in operating activities (nine months): $(253,975).
- Negative: Working capital deficit and accumulated losses - Working capital deficit at Dec 31, 2024: $5,323,014; Accumulated deficit: $(110,642,891).
- Negative: Material weaknesses in controls (audit committee expertise and combined CEO/CFO roles) and substantial doubt about going concern noted by management.

Key facts & stats (extracted)

- Shares outstanding: 407,071,028 (as of August 11, 2025).
- Cash and cash equivalents (Dec 31, 2024): $3,016; Cash at Mar 31, 2024: $11,991.
- Total current assets (Dec 31, 2024): $94,467; Total liabilities (Dec 31, 2024): $5,974,481.
- Current liabilities (Dec 31, 2024): $5,417,481 (accounts payable $2,099,924; accounts payable related party $119,451; accrued interest $554,474; notes & convertible notes payable $1,437,307; income tax payable $1,060,825).
- Total notes & convertible notes payable (face values summarized): $1,994,307 (short + long term combined as disclosed).
- Convertible notes issued subsequent to period: $360,000 aggregate (Jan 1, 2025 - Aug 12, 2025); 6% interest; convertible at $0.01/share.
- Warrants outstanding (Dec 31, 2024): 74,412,829.
- Patents/IP: 8 U.S. and 12 foreign patents issued; 2 foreign patents allowed; 15 U.S. and 41 foreign patent‑pending applications.
- Revenue recognition source: royalties from EndoPure licensing agreement (entered Sept 26, 2024).
- Loss from operations (three months ended Dec 31, 2024): $(66,591).
- Interest expense (three months ended Dec 31, 2024): $(33,764) - decreased vs prior quarter due to amortization of debt discounts.
- Net loss per common share - basic and diluted: $(0.00) (rounded).

Operational highlights

- Licensing deal with EndoPure grants Brazil exclusivity and South America commercialization after approvals; financials include royalty 5% and minimum prepaid royalties.
- Positive preclinical results across multiple programs (Parkinson's dose‑response, chronic pain, stability and other animal studies); management emphasizing partner/licensing strategy to advance clinical development.

Risks & red flags to watch

- Very low cash on hand and a working capital deficit - company must raise capital in near term to fund operations.
- Substantial debt outstanding, some notes in default historically; accrued interest and convertible instruments can dilute equity if converted (conversion prices as low as $0.01 cited).
- Management & governance issues flagged (material weaknesses in disclosure controls; CEO also serving as interim CFO).
- Going concern: management explicitly states "substantial doubt" about continuing for 12 months without additional financing.

Bottom line: GB Sciences (OTCMKTS: GBLX) has valuable IP and early commercial traction from a licensing deal, but the company is operating with minimal cash, mounting liabilities and recurring losses. Short‑term survival depends on further financing or partner payments; long‑term value depends on successful clinical development or meaningful license revenue.